Looking for ways to increase your exposure to investors?
Take part in the Innovator’s Pitch Challenge at Digital RESI!

Apply Now

Redefining Early Stage Investments (RESI)
Conference Series

Connecting Early Stage Products With Capital & Channel Partners

Upcoming RESI Conference:

Welcome to RESI Conference Series

Helping fund life science companies from Grants to Series B

The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners. The goal was to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. What‘s unique about RESI is that the event is cross border and cross domain, connecting startups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health, the “4 Ds”. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.

  • 1:1 Ratio of Entrepreneurs to Investors
  • Cutting-edge Technologies across Drugs, Devices, Diagnostics, & Digital Health
  • 10 Type of Early-Stage Investors from North America, Europe, Asia…
  • A Full Day of One-to-One Partnering Meetings and Networking
  • Insightful Investor Panels and Entrepreneur Workshops
  • Global Gathering of Tech Hubs & Their Constituents

LSN invites tech hubs, entrepreneurs, investors, strategic partners, and service providers to the RESI Conference.

YOU ARE INVITED
Incubators, tech transfer offices, universities, hospitals, research labs and their constituents to get on the radar of investors and channel partners.Biotech, Medtech, Diagnostics and Digital Health to source global investors and strategic partners, create relationships, and potentially, secure funding
Tech Hubs & Their ConstituentsEarly Stage Fundraising Companies
Seed $15K – $2MMSeries A $2MM – $10MM &
Series B $10MM – $50MM

RESI Conference Series Overview

RESI is the Biggest Partnering Conference in The North America Focuses on The Early-Stage Life Science Investments and Strategic Partnerships.

In the past 7 years, over 300 companies have raised $400+ MM through 30 RESI Conferences.

Customer Testimonials

“We have been a long time RESI attendees as we have recognized the value that it brings in connecting entrepreneurs with early stage investors like us. The Digital RESI will allow us to continue, and expand, the opportunity to interact while we circumvent travel and meeting restrictions.”

Christopher de Souza
Director, Broadview Ventures

“As Title Sponsor we are pleased to see responsible choices being made about taking RESI Europe digital, and we’re excited to see partnering expand from a one day physical event to a three day virtual event… Our workshop on “Negotiating Term Sheets” will provide a great learning opportunity to all of the investors and fundraising CEOs who need this critical information.”

Angus McQuilken
Industry Relationship Executive – Life Sciences, McDermott Will & Emery

Digital RESI – Three Day Conference Registration

When: November 17 – 19, 2020

Where: resiconference.com

1-Day Ticket

$495
  • – Full Day of Partnering
  • – Meet and Network with Global Partners
  • – Access all conference content
  • Premier Package
    Any RESI Ticket + $500 Upgrade Fee
    Learn More About the Differences

3-Day Ticket

$$750
  • – 3 Full Days of Partnering
  • – Meet and Network with Global Partners
  • – Access all conference content
  • Premier Package
    Any RESI Ticket + $500 Upgrade Fee
    Learn More About the Differences

Click Each Section Below for Details

Digital RESI is a dedicated global partnering event. RESI has the most powerful partnering platform because we can match companies and partners based on stage of development and product fit. The core value is our 1:1 partnering, that RESI has used since 2013. The partnering software is owned and operated by our partner Meeting Mojo, which is implementing a video meeting component embedded in the application. Any RESI attendee can use this video capability to “attend” their scheduled meeting. The challenge for all the attendees will be the geographic time zone issues and that may require some flexibility. Fortunately, being virtual and being able to extend the conference from a one day physical to a three-day virtual conference means more availability to find mutual time slots that will work for both parties.

RESI is unique in that we dedicate most of our panels to the ten categories of investors and partners who play in the early-stage space, cross-border and across the silos of drugs, devices, diagnostics and digital health. What attendees learn from these panels is who the right players are, the best way to reach out, how they source technology (including RESI), how they vet companies and how they help early stage companies with whom they have relationships develop. The information that entrepreneurs receive from these panels is invaluable in helping them understand the nuances of how all the different players in the space approach early stage startups.

Each company’s page will feature a prerecorded 4-min pitch, along with other introductive materials. Following RESI, the pitching companies will be divided into live Q&A sessions based on sector, in which companies will deliver a 1 min elevator pitch to a panel of relevant investors, followed by 5 min of Q&A. Please contact research@lifescienceantion.com if you’d like to participate on the investor Q&A panel.
The RESI exhibitors and sponsors will be featured on a dedicated page with a virtual exhibitor booth, showcasing their services and the value they can provide. Participating tech hubs can highlight their programs and constituent companies.
Register Now

Digital RESI November Investor Panel

Tuesday, November 17th, 2020

10:00 – 11:00am EST

EARLY STAGE THERAPEUTICS INVESTORS

Bringing the Newest Therapies to the Clinic

This panel aims to bring a diverse group of experts & senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:

  • How they make decisions
  • What can startups do to be more attractive?
  • Areas of high need
  • Overcrowded areas
  • Common mistakes/red flags

The moderator will guide the discussion through topics including how the investors source & vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.

Tuesday, November 17th, 2020

2:00 – 3:00pm EST

DIAGNOSTICS INVESTORS

New Generation of Technologies Changing Treatment Paradigms

This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:

  • Current areas of interest
  • Current challenges in this ecosystem – Navigating the competitive landscape
  • Commonly observed red flags
  • Successful deals

Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

Wednesday, November 18th, 2020

10:00 – 11:00am EST 

MEDICAL DEVICE INVESTORS

Investing in Novel Engineering

This panel focuses on investment in new medical devices from development stage through to early commercialization. Topics may include:

  • What are investors looking for?
    • Areas of interest
    • Overcrowded areas
  • How to approach an investor
  • Successful deals they’ve done before
  • Common mistakes/Red flags

Panelists will discuss how to meet the challenges of raising financing for a new device and advise startups on how to make the investment case for their novel technology. Panelists will also explore what technology areas are of top interest to them and how a startup can get them into dialogue regarding an investment or deal.

Wednesday, November 18th, 2020

2:00 – 3:00pm EST

DIGITAL HEALTH

Leveraging Software to Lower Costs and Improve the Quality of Care

This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:

  • In what kinds of digital health technologies are they interested in investing?
  • What metrics and evidence do you look for in a digital health startup?
  • How can an early stage digital health company demonstrate the value of their products?
  • What are the main challenges for startups raising capital in this space?

The moderator and panelists will discuss this rapidly evolving field of healthcare investment, and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.

Thursday, November 19th, 2020

10:00 – 11:00am EST

BIG PHARMA

Pipeline Strategy for Preclinical and Early Clinical Assets

In recent years, big pharma companies have begun looking outwards for innovative new therapeutics to add to their pipelines. This panel brings togerther speakers from various big pharma companies discussing topics such as:

  • How big pharma sources assets
  • The evaluation and investment process
  • Key factors of interest
  • How early-stage big pharma is willing to look

These panelists will shed light on the process that big pharma goes through when sourcing early-stage assets and advise startups on how they can best make a case for themselves. Panelists will also explore various trends within the therapeutics marketplace, what assets are of interest to their company, and what they think will be big in the future.

Thursday, November 19th, 2020

2:00 – 3:00pm EST

CORPORATE VENTURE CAPITAL

The Corporate Landscape Morphed & New Opportunities Abound

This panel discusses what strategies are employed by corporate venture capital firms for investments and partnerships with early-stage companies. Potential topics for the panel include:

  • What corporate VCs look for in companies
  • What working with a corporate VC entails
  • What companies should do to be relevant to the corporate VC

Panelists could also discuss the relationship between the corporate venture capital firm and the parent company and how it affects investment criteria.